Clinical Trials Directory

Trials / Completed

CompletedNCT04697589

Acute Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects

Acute Dose-response Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects: Randomized, Cross-over, Double-blind Clinical Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Activ'inside · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

It is well established that endothelial dysfunction is an early predictor of cardiovascular events in at-risk patients. Finding safe and effective product able to improve endothelial function is of public health interest. Many clinical studies have shown that monomer of flavanols from cocoa significantly improved endothelial function, in particular endothelium-dependent flow-mediated dilation (ED-FMD) after a single dose. Grape is also a main source of flavanol monomers, that's why many human studies have shown significant effects of grape-derived products on endothelial function within 2 hours following a single dose intake. The objective of this study is to assess the effect of 2 doses of a proprietary and standardised botanical blend rich in polyphenols (SBRP), on ED-FMD in fasting conditions, in comparison to a placebo, in healthy adults. This blend is made of two botanical extracts: a grape extract and a blueberry extract. In order to provide supportive evidence on the mechanisms and biological plausibility to the clinical effects of the product, appropriate biological parameters and circulating metabolites will be assayed.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMemophenol 300 mg300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
DIETARY_SUPPLEMENTMemophenol 600 mg600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
DIETARY_SUPPLEMENTPlaceboColored maltodextrin

Timeline

Start date
2021-02-01
Primary completion
2023-12-11
Completion
2023-12-11
First posted
2021-01-06
Last updated
2024-02-14

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04697589. Inclusion in this directory is not an endorsement.